NRC
NRC Health
20.20$
+0.5%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +1.9% | -1.2% | -1.5% | +10.7% | +0.6% | +2.0% | +4.6% | -4.0% | -0.6% | -0.2% | +1.2% | |
| – | -1.5% | -17.8% | -15.3% | +22.1% | -5.3% | +4.1% | +24.1% | -19.4% | -0.9% | -1.1% | +14.1% | |
| – | +73.8% | -74.5% | -71.5% | +613.6% | +22.3% | -40.9% | +110.8% | -57.9% | +86.5% | -38.5% | +30.6% | |
| – | +73.8% | -74.5% | -71.5% | +613.6% | +22.3% | -40.9% | +110.8% | -57.9% | +86.5% | -38.5% | +30.6% | |
| – | -15.5% | -11.0% | -7.4% | +13.2% | -4.3% | +2.4% | +12.1% | -0.8% | -8.7% | -2.8% | +20.6% | |
| – | – | – | +0.0% | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.0% | +0.0% | +7.5% | -0.1% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | -2.3% | -2.4% | -2.4% | +93.6% | -3.6% | -3.7% | -3.9% | -4.0% | -4.2% | -2.8% | -2.9% | |
| – | +18.0% | +14.3% | -6.0% | +23.2% | +4.2% | +4.2% | +13.8% | +1.1% | -0.4% | +0.1% | +7.1% | |
| – | -11.3% | +34.9% | -6.4% | -3.2% | -19.0% | +5.3% | -4.9% | +7.3% | -5.0% | +5.1% | -9.0% | |
| – | -12.9% | +72.3% | +14.2% | -47.4% | -38.7% | +22.2% | -39.9% | +2.1% | +0.0% | +0.0% | +0.0% | |
| – | -8.6% | +84.2% | -48.3% | +108.9% | -53.9% | +70.0% | -41.9% | -7.3% | +271.7% | -45.2% | -40.5% | |
| – | +108.1% | -6.5% | -6.9% | +75.1% | +28.9% | +1.3% | +31.3% | -1.3% | -1.3% | -1.3% | +16.2% | |
| – | -15.4% | -24.5% | +8.8% | -13.9% | -9.6% | -5.2% | -28.1% | -32.9% | -2.3% | -3.5% | -51.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -0.6% | -2.4% | -0.2% | -0.7% | -1.6% | -1.7% | -1.4% | -0.3% | -3.5% | +0.5% | +0.4% |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.